SCHEDULE: Fresenius Sells Humacyte Shares, Stake Drops Below 5%

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG have reduced their stake in Humacyte, Inc. to below 5% following a series of share sales.

Summary

• Fresenius Medical Care Holdings, Inc. (FMCH) and Fresenius Medical Care AG (FME AG) have filed an amendment to their Schedule 13D, reporting a reduction in their beneficial ownership of Humacyte, Inc. common stock.
• As of August 17, 2026, FMCH beneficially owns 13,603,235 shares, representing approximately 4.9% of Humacyte's outstanding voting shares.
• This ownership level is calculated based on 277,798,105 shares outstanding as of August 10, 2026.
• The reduction in ownership is due to a series of sales executed between August 10 and August 17, 2026, under a Rule 10b5-1 Plan.
• Cassie McLean has assumed new leadership roles within FME AG and FMCH, succeeding Craig Cordola who retired.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant share sales by a major holder, indicating a potential lack of confidence or strategic shift.

Positives

• The filing clearly outlines the reduction in shareholding, providing transparency to the market.
• The sales were conducted under a pre-established Rule 10b5-1 Plan, suggesting a structured and potentially pre-planned divestment strategy.

Negatives

• Significant sales of Humacyte stock by a major holder (Fresenius) have occurred, reducing their stake below the 5% threshold.
• The total proceeds from sales between August 10 and August 17, 2026, amounted to approximately $2,645,000.
• The weighted average sale price decreased throughout the week of sales, from $0.7249 on August 10 to $0.5547 on August 17.

Risks

• The reduction in stake by a significant holder could be interpreted by the market as a lack of confidence in Humacyte's future prospects.
• Further sales by Fresenius could exert downward pressure on Humacyte's stock price.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Humacyte, Inc. It primarily reports on changes in beneficial ownership by Fresenius Medical Care entities.

Management Comments

• Ms. Cassie McLean assumed office as a member of the Management Board of FME AG and Chief Executive Officer of FME AG's global operating segment Care Delivery, and as President and CEO of FMCH, succeeding Mr. Craig Cordola who retired.

Industry Context

StockSavvy.ai notes that significant divestments by major shareholders can signal shifts in strategic focus or perceived value. For Humacyte, a company in the biotechnology sector, such moves by a large entity like Fresenius Medical Care could impact investor sentiment and potentially influence future financing or partnership opportunities.

Management Changes

Stakeholder Impact

• Shareholders: The significant sales by Fresenius may lead to increased stock price volatility and potentially a downward trend, impacting shareholder value.
• Creditors: No direct impact mentioned, but a sustained decline in stock price could indirectly affect perceived company stability.
• Employees: While not directly mentioned, a significant shift in major shareholder sentiment could create uncertainty within the company.

Next Steps

• Fresenius Medical Care entities will continue to monitor their investment in Humacyte, Inc.
• Humacyte, Inc. will continue its operations and strategic initiatives.

Key Dates

Recommendation

While the significant share sales by Fresenius are a negative signal, the filing itself is primarily a disclosure of ownership change and does not contain operational or financial performance data for Humacyte. The reduction in stake to just below 5% suggests Fresenius is no longer a controlling or significantly influential shareholder from a disclosure perspective, but they may still hold a substantial investment. Without more information on Humacyte's performance, a 'hold' recommendation is prudent, acknowledging the negative sentiment from the sales while awaiting further company-specific news.

Keywords

Humacyte, Fresenius Medical Care, Schedule 13D, Shareholder, Stock Sale, Beneficial Ownership, Rule 10b5-1 Plan